Rotarescu C, Maruntelu I, Rotarescu I, Constantinescu A, Constantinescu I
J Clin Med. 2024; 13(7).
PMID: 38610733
PMC: 11012255.
DOI: 10.3390/jcm13071968.
Wanas H, Kamel M, William E, Fayad T, Abdelfattah M, Elbadawy H
J Clin Lab Anal. 2023; 37(19-20):e24969.
PMID: 37789683
PMC: 10681408.
DOI: 10.1002/jcla.24969.
Galvez C, Boza P, Gonzalez M, Hormazabal C, Encina M, Azocar M
Front Pharmacol. 2023; 14:1044050.
PMID: 36998611
PMC: 10043346.
DOI: 10.3389/fphar.2023.1044050.
Mulder T, van Eerden R, de With M, Elens L, Hesselink D, Matic M
Front Genet. 2021; 12:711943.
PMID: 34306041
PMC: 8296839.
DOI: 10.3389/fgene.2021.711943.
Saiz-Rodriguez M, Almenara S, Navares-Gomez M, Ochoa D, Roman M, Zubiaur P
Biomedicines. 2020; 8(4).
PMID: 32331352
PMC: 7235792.
DOI: 10.3390/biomedicines8040094.
The Impact of on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center.
Abdel-Kahaar E, Winter S, Tremmel R, Schaeffeler E, Olbricht C, Wieland E
Front Genet. 2019; 10:871.
PMID: 31616470
PMC: 6775237.
DOI: 10.3389/fgene.2019.00871.
Evaluation of tacrolimus-related CYP3A5 genotyping in China: Results from the First External Quality Assessment Exercise.
Lin G, Zhang X, Zhang K, Han Y, Tan L, Li J
J Clin Lab Anal. 2018; 32(8):e22563.
PMID: 29708622
PMC: 6817186.
DOI: 10.1002/jcla.22563.
Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.
Vanhove T, Annaert P, Lambrechts D, Kuypers D
Pharmacogenomics J. 2016; 17(6):556-562.
PMID: 27378609
DOI: 10.1038/tpj.2016.49.
Genotype-guided tacrolimus dosing in African-American kidney transplant recipients.
Sanghavi K, Brundage R, Miller M, Schladt D, Israni A, Guan W
Pharmacogenomics J. 2015; 17(1):61-68.
PMID: 26667830
PMC: 4909584.
DOI: 10.1038/tpj.2015.87.
Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.
Moes D, van der Bent S, Swen J, van der Straaten T, Inderson A, Olofsen E
Eur J Clin Pharmacol. 2015; 72(2):163-74.
PMID: 26521259
PMC: 4713720.
DOI: 10.1007/s00228-015-1963-3.
Multigene predictors of tacrolimus exposure in kidney transplant recipients.
Pulk R, Schladt D, Oetting W, Guan W, Israni A, Matas A
Pharmacogenomics. 2015; 16(8):841-54.
PMID: 26067485
PMC: 4527535.
DOI: 10.2217/pgs.15.42.
Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients.
Zununi Vahed S, Ardalan M, Samadi N, Omidi Y
Bioimpacts. 2015; 5(1):45-54.
PMID: 25901296
PMC: 4401167.
DOI: 10.15171/bi.2015.12.
The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients.
de Jonge H, Elens L, de Loor H, van Schaik R, Kuypers D
Pharmacogenomics J. 2014; 15(2):144-52.
PMID: 25287072
DOI: 10.1038/tpj.2014.49.
Role of pharmacogenomics in dialysis and transplantation.
Birdwell K
Curr Opin Nephrol Hypertens. 2014; 23(6):570-7.
PMID: 25162201
PMC: 4220684.
DOI: 10.1097/MNH.0000000000000065.
Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation.
Moes D, Swen J, den Hartigh J, van der Straaten T, van der Heide J, Sanders J
CPT Pharmacometrics Syst Pharmacol. 2014; 3:e100.
PMID: 24522145
PMC: 3944116.
DOI: 10.1038/psp.2013.78.
Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.
Provenzani A, Santeusanio A, Mathis E, Notarbartolo M, Labbozzetta M, Poma P
World J Gastroenterol. 2014; 19(48):9156-73.
PMID: 24409044
PMC: 3882390.
DOI: 10.3748/wjg.v19.i48.9156.
The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
Hesselink D, Bouamar R, Elens L, van Schaik R, van Gelder T
Clin Pharmacokinet. 2013; 53(2):123-39.
PMID: 24249597
DOI: 10.1007/s40262-013-0120-3.
